Abstract:Background Cancer-related pain often requires opioid treatment with opioid-induced constipation (OIC) as its most frequent gastrointestinal side-effect. Both for prevention and treatment of OIC osmotic (e.g. polyethylene glycol) and stimulant (e.g. bisacodyl) laxatives are widely used. Newer drugs such as the peripherally acting μ-opioid receptor antagonists (PAMORAs) and naloxone in a fixed combination with oxycodone have become available for the management of OIC. This systematic review and meta -analysis aims to give an overview of the scientific evidence on pharmacological strategies for the prevention and treatment of OIC in cancer patients. Methods A systematic search in PubMed, Embase, Web of Science and the Cochrane Library was completed from inception up to 22 October 2022. Randomized and non-randomized studies were systematically selected. Bowel function and adverse drug events were assessed. Results Twenty trials (prevention: five RCTs and three cohort studies; treatment: ten RCTs and two comparative cohort studies) were included in the review. Regarding the prevention of OIC, three RCTs compared laxatives with other laxatives, finding no clear differences in effectivity of the laxatives used. One cohort study showed a significant benefit of magnesium oxide compared with no laxative. One RCT found a significant benefit for the PAMORA naldemedine compared with magnesium oxide. Preventive use of oxycodone/naloxone did not show a significant difference in two out of three other studies compared to oxycodone or fentanyl. A meta -analysis was not possible. Regarding the treatment of OIC, two RCTs compared laxatives, of which one RCT found that polyethylene glycol was significantly more effective than sennosides. Seven studies compared an opioid antagonist (naloxone, methylnaltrexone or naldemedine) with placebo and three studies compared different dosages of opioid antagonists. These studies with opioid antagonists were used for the meta -analysis. Oxycodone/naloxone showed a significant improvement in Bowel Function Index compared to oxycodone with laxatives (MD −13.68; 95 % CI −18.38 to −8.98; I 2 = 58 %). Adverse drug event rates were similar amongst both groups, except for nausea in favour of oxycodone/naloxone (RR 0.51; 95 % CI 0.31–0.83; I 2 = 0 %). Naldemedine (NAL) and methylnaltrexone (MNTX) demonstrated significantly higher responder rates compared to placebo (NAL: RR 2.07, 95 % CI 1.64–2.61, I 2 = 0 %; MNTX: RR 3.83, 95 % CI 2.81–5.22, I 2 = 0 %). With regard to adverse events, abdominal pain was more present in treatment with methylnaltrexone and diarrhea was significantly more present in treatment with naldemedine. Different dosages of methylnaltrexone were not significantly different with regard to both efficacy and adverse drug event rates. Conclusions Magnesium oxide and naldemedine are most likely effective for prevention of OIC in cancer patients Naloxone in a fixed combination with oxycodone, naldemedine and methylnaltrexone effectively treat OIC in cancer patients with acceptable adverse events. However, their effect has not been compared to standard (osmotic and stimulant) laxatives. More studies comparing standard laxatives with each other and with opioid antagonists are necessary before recommendations for clinical practice can be made.

Metoclopramide for analgesia in renal colic: a narrative systematic review

Efficacy and Safety of Ketamine Versus Opiates in the Treatment of Patients with Renal Colic: A Systematic Review and Meta-analysis

Clinical efficacy of acupuncture for pain relief from renal colic: A meta-analysis and trial sequence analysis

Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis

Metamizole in the Management of Musculoskeletal Disorders: Current Concept Review

S1009 Role of Metoclopramide During Endoscopy in Patients With Upper Gastrointestinal Bleeding

Is metoclopramide beneficial for the postpyloric placement of nasoenteric tubes? A systematic review and meta-analysis of randomized controlled trials

Sterile water injections for management of renal colic pain: a systematic review

[Renal colic: How to calm and optimize the stone expulsion? Which treatment for pregnant women and children?]

Efficacy of acupoint injection of metoclopramide for post-chemotherapy vomiting: A systematic review and meta-analysis

Medical Treatment for Renal Colic and Stone Expulsion

Acupuncture for response and complete pain relief time of acute renal colic: Secondary analysis of a randomized controlled trial

Retrospective study on pain management pathway for patients with suspected renal/ ureteric colic in a U.K. accidents and emergency department: A quality improvement project

A Standardized Pain Management Protocol Improves Timeliness of Analgesia Among Emergency Department Patients With Renal Colic

Pharmacological interventions for reducing catheter-related bladder discomfort in patients undergoing elective surgeries under general anaesthesia: A systematic review and meta-analysis

Piroxicam and paracetamol in the prevention of early recurrent pain and emergency department readmission after renal colic: Randomized placebo‐controlled trial

Analgesia for the treatment of acute pancreatitis: a protocol for a systematic review and network meta-analysis

Haloperidol for Pain Management: A Narrative Review

Prokinetics for the treatment of functional dyspepsia: an updated systematic review and network meta-analysis

The systematic review and meta-analysis evaluated the efficacy and safety of nefopam for catheter-related bladder discomfort based on randomized controlled trials

Pain Relieving Effect of Sublingual Glycerol Trinitrate in Renal Colic: a Randomized Placebo-Controlled Trial